This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Michael J. Reding, MD; Fletcher H. McDowell, MD
The Burke Rehabilitation Center 785 Mamaroneck Ave White Plains, NY 10605

Arch Neurol. 1987;44(5):475.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We appreciate Dr Ferguson's interest in our study of antidepressant therapy following stroke. He raises several questions that we would like to address as follows.

The number of patients in each clinical group listed in Table 1 is the sum of males and females. Thus, there were six patients completing the placebo phase and 11 patients completing the trazodone phase of the study. Five patients with abnormal Zung scores received placebo, and four were given trazodone. The number of patients in each clinical group is sufficient for valid analysis using the Wilcoxon Rank Sum Test as mentioned below. We discuss in the text of our report that the small number of patients does not allow comment concerning dose-response data. No meaningful comments can be made concerning the response of patients who reached the target dose of trazodone versus those tolerating only lower dosages.

Doctor Ferguson's comment that the mean initial . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?